Press Releases Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Market Closed - OTC Markets Other stock markets 02:57:12 2024-05-08 pm EDT			5-day change	1st Jan Change
0.19 ^USD	+6.26%		-2.51%	+97.92%

Apr. 18	Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose	CI
Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)	May. 02	AQ
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers	Apr. 18	AQ
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation	Apr. 16	AQ
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting	Apr. 11	AQ
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium	Mar. 27	AQ
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines	Mar. 12	AQ
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting	Mar. 07	AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM ABSTRACT FOR POSTER PRESENTATION AT 2024 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING	Mar. 01	AQ
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting	Feb. 29	AQ
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call	Feb. 15	AQ
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services	Feb. 14	AQ
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant	Dec. 18	AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma	Nov. 15	AQ
Provectus: Q3 Earnings Snapshot	Nov. 14	AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma	Nov. 13	AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL PV-10 VACCINE ADJUVANT DATA AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	Nov. 07	AQ
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	Nov. 06	AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	23-08-08	AQ
Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	23-08-07	AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SOCIETY FOR MELANOMA RESEARCH 2023 CONGRESS	23-08-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Provectus Biopharmaceuticals, Inc.

Equities

PVCT

US74373P1084

Press Releases

Filters